Antimicrobial-resistant surveillance reports of 25 hospitals in Thailand in 2022

This is the data set for the study article "Local and timely antimicrobial resistance data for local and national actions: the early implementation of an automated tool for data analysis at local hospital level in Thailand" <br> Abstract of the article <strong>Background</strong> In low and middle-income countries (LMICs), hospitals can rarely utilize their own antimicrobial resistance (AMR) data in a timely manner. <strong>Objectives </strong> To evaluate the utility of local AMR data generated by an automated tool in the real-world setting <strong>Methods </strong> From 16 December 2022 to 10 January 2023, on behalf of the Health Administration Division, Ministry of Public Health (MoPH) Thailand, we trained 26 public tertiary-care and secondary-care hospitals to utilize the AutoMated tool for Antimicrobial resistance Surveillance System (AMASS) with their own microbiology and hospital admission data files via two online meetings, one face-to-face meeting and on-line support. All meetings were recorded on video, and feedback was analysed. <strong>Results</strong> Twenty-five hospitals successfully generated and shared the AMR reports with the MoPH by 28 February 2023. In 2022, the median frequency of hospital-origin bloodstream infections (BSI) caused by carbapenem-resistant <em>Escherichia coli</em> (CREC) was 129 (range 0-1204), carbapenem-resistant <em>Klebsiella pneumoniae</em> (CRKP) was 1306 (range 0-5432), and carbapenem-resistant <em>Acinetobacter baumannii</em> (CRAB) was 4472 (range 1460-11968) per 100,000 patients tested for hospital-origin BSI. The median number of all-cause in-hospital deaths with hospital-origin AMR BSI caused by CREC was 1 (range 0-18), CRKP was 10 (range 0-77) and CRAB was 56 (range 7-148). Participating hospitals found that the data obtained could be used to support their antimicrobial stewardship and infection prevention control programmes. <strong>Conclusions </strong> Local and timely AMR data is crucial for local and national actions. MoPH Thailand is inviting all 127 public tertiary-care and secondary-care hospitals to utilize the AMASS. Using any appropriate analytical software or tools, all hospitals in LMICs that have electronic data records should analyse and utilise their data for immediate actions. <br>

本数据集配套于研究论文《适配本土与国家行动的本地化及时抗菌药物耐药性数据：泰国地方医院层级自动化数据分析工具的早期落地实践》
论文摘要：
【背景】在低收入和中等收入国家（low and middle-income countries, LMICs），医院极少能够及时利用自身的抗菌药物耐药性（antimicrobial resistance, AMR）数据。
【目标】本研究旨在评估真实场景下自动化工具生成的本地化抗菌药物耐药性数据的应用价值。
【方法】2022年12月16日至2023年1月10日，我们受泰国公共卫生部（Ministry of Public Health, MoPH）卫生行政司委托，通过2次线上会议、1次线下会议及线上技术支持，对26家公立三级、二级公立医院开展培训，使其能够利用自身微生物学与住院患者数据文件，运行抗菌药物耐药性监测自动化工具（AutoMated tool for Antimicrobial resistance Surveillance System, AMASS）。所有会议均进行了录像，并对反馈意见进行了分析。
【结果】截至2023年2月28日，共有25家医院成功生成并向泰国公共卫生部提交了抗菌药物耐药性报告。2022年，每10万名接受医院源性血流感染（bloodstream infections, BSI）检测的患者中，由耐碳青霉烯类大肠埃希菌（carbapenem-resistant Escherichia coli, CREC）引起的医院源性血流感染的中位数频次为129（区间：0~1204）；由耐碳青霉烯类肺炎克雷伯菌（carbapenem-resistant Klebsiella pneumoniae, CRKP）引起者为1306（区间：0~5432）；由耐碳青霉烯类鲍曼不动杆菌（carbapenem-resistant Acinetobacter baumannii, CRAB）引起者为4472（区间：1460~11968）。由CREC、CRKP、CRAB引发的医院源性抗菌药物耐药性血流感染患者的全因住院死亡中位数分别为1例（区间：0~18）、10例（区间：0~77）、56例（区间：7~148）。参与医院反馈，所获取的数据可用于支撑其抗菌药物管理与感染预防控制工作。
【结论】本地化且及时的抗菌药物耐药性数据对于地方与国家层面的防控行动至关重要。泰国公共卫生部现邀请全国127家公立三级、二级公立医院使用AMASS工具。所有拥有电子数据记录的低收入和中等收入国家医院，均可通过任意合适的分析软件或工具，对自身数据进行分析并用于即时防控行动。